All In MedTech

Device Trial Radar · NCT01857934

Therapy for Children With Advanced Stage Neuroblastoma

Neuroblastoma Protocol 2012: Therapy for Children With Advanced Stage High-Risk Neuroblastoma

Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

153

Actual

Start

Jul 5, 2013

Primary completion

Oct 21, 2021

Study completion Dec 31, 2025

Sponsor

Lead sponsor
St. Jude Children's Research HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Cookies for Kids' Cancer; CURE Childhood Cancer, Inc.
First posted
May 20, 2013

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Neuroblastoma is the most common extracranial solid tumor in childhood, with nearly 50% of patients presenting with widespread metastatic disease. The current treatment for this group of high-risk patients includes intensive multi-agent chemotherapy (induction) followed by myeloablative therapy with stem-cell rescue (consolidation) and then treatment of minimal residual disease (MRD) with isotretinoin. Recently a new standard of care was established by enhancing the treatment of MRD with the addition of a monoclonal antibody (ch14.18) which targets a tumor-associated antigen, the disialoganglioside GD2, which is uniformly expressed by neuroblasts. Despite improvement in 2-year event-free survival (EFS) of 20%, more than one-third of children with high-risk neuroblastoma (HR defined in) still cannot be cured by this approach. Therefore, novel therapeutic approaches are needed for this subset of patients. This study will be a pilot Phase II study of a unique anti-disialoganglioside (anti-GD2) monoclonal antibody (mAb) called hu14.18K322A, given with induction chemotherapy. PRIMARY OBJECTIVE: * To study the efficacy \[response: complete remission + partial remission (CR+PR)\] to two initial courses of cyclophosphamide and topotecan combined with hu14.18K322A (4 doses/course followed by GM-CSF) in previously untreated children with high-risk neuroblastoma. * To estimate the event-free survival of patients with newly diagnosed high-risk neuroblastoma treated with the addition of hu14.18K322A to treatment. SECONDARY OBJECTIVES: * To study the feasibility of delivering hu14.18K322A to 6 cycles induction chemotherapy and describe the antitumor activity (CR+PR) of this 6 course induction therapy. * To estimate local control and pattern of failure associated with focal intensity modulated or proton beam radiation therapy dose delivery in high-risk abdominal neuroblastoma. * To describe the tolerability of four doses of hu14.18K322A with allogeneic natural killer (NK) cells from an acceptable parent, in the immediate post-transplant period \[day +2 - +5 after peripheral blood stem cell (PBSC) infusion\] in consenting participants. * To describe the tolerability of hu14.18K322A with interleukin-2 and GM-CSF as treatment for minimal residual disease (MRD).

Conditions

  • Neuroblastoma

Interventions

  • cyclophosphamideDrug

    Given intravenously (IV)

  • topotecanDrug

    Given IV

  • hu14.18K322ABiological

    Given IV

  • peripheral blood stem cell harvestProcedure

    Following evaluation and approval by a member of the transplant staff and completion of the consent form by the participant, collection of peripheral blood stem cells (PBSC) may take place.

  • surgical resectionProcedure

    The primary tumor will be resected surgically following two initial courses of chemotherapy, if feasible. Patients who are unable to have their primary tumor resected after the initial two courses of induction chemotherapy will undergo surgery for resection of the primary tumor mass and careful lymph node staging.

  • cisplatinDrug

    Given IV

  • etoposideDrug

    Given IV

  • doxorubicinDrug

    Given IV

  • vincristineDrug

    Given IV

  • busulfanDrug

    Given IV

  • melphalanDrug

    Given IV

  • peripheral blood stem cell transplantationBiological

    Transplantation of previously harvested peripheral blood stem cells.

  • natural killer cell infusionBiological

    Natural killer (NK) cells obtained from a suitable donor will be given together with hu14.18K322A prior to early hematopoietic cell recovery. In the event there is not a suitable parental donor, consenting participants will receive an additional course of hu14.18K322A.

  • radiation therapyRadiation

    Radiation therapy to the primary and metastatic disease sites will follow peripheral blood stem cell transplant with the exception of any patient requiring emergent radiotherapy. External beam radiotherapy will be delivered to the primary site and select metastatic and bulky nodal sites.

  • GM-CSFBiological

    Given subcutaneously (SQ)

  • G-CSFBiological

    Given subcutaneously (SQ)

  • mesnaDrug

    Given IV

  • levetiracetamDrug

    Given IV

  • interleukin-2Biological

    Given by continuous infusion during MRD maintenance, and SQ during induction.

  • IsotretinoinDrug

    Given orally (PO)

  • CliniMACSDevice

    The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate [Complete Response + Very Good Partial Response + Partial Response (CR + VGPR + PR)]Time frame: After two initial courses of chemotherapy (approximately 6 weeks after enrollment)
  2. Event-free Survival (EFS)Time frame: 3 years, from time of enrollment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • St. Jude Children's Research Hospital

    Memphis, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.